Trials / Active Not Recruiting
Active Not RecruitingNCT03690388
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 187 (actual)
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior vascular endothelial growth factor receptor (VEGFR)-Targeted therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cabozantinib | Tablets containing 60-mg or 20-mg cabozantinib once daily orally. |
| DRUG | Placebo | Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally. |
Timeline
- Start date
- 2018-10-05
- Primary completion
- 2020-08-19
- Completion
- 2026-07-31
- First posted
- 2018-10-01
- Last updated
- 2025-09-25
- Results posted
- 2023-05-18
Locations
164 sites across 25 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Croatia, Czechia, France, Germany, Hong Kong, Hungary, Israel, Italy, Mexico, Netherlands, Poland, Romania, Russia, South Korea, Spain, Taiwan, Thailand, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03690388. Inclusion in this directory is not an endorsement.